Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Delivery of Factor Xa into transfusable platelets to increase their natural coagulability

FY 2020-21

Summary
Platelets are blood cells that detect and adhere to sites of vascular damage, where they release pro-coagulant contents to initiate blood clotting. Failure to control bleeding after injury, such as during trauma, childbirth and surgery, accounts for more than half of all operating room deaths. Platelet transfusion is an essential treatment option to stop severe bleeding, but is not always effective, especially after significant blood loss. A strategy to improve platelet function during severe bleeds is to manipulate their internal composition by adding additional pro-coagulant proteins that enhance their natural ability to form a blood clot. This project aims to genetically engineer donor platelets to produce new coagulation factors so that after administration, they stop bleeding faster and create stronger clots than unmodified platelets. Generating new coagulation factors in platelets will be achieved by using lipid nanoparticle (LNP) drug delivery technology. Similar LNPs that are being used in leading COVID-19 vaccine candidates developed by Moderna and BioNtech will be used to deliver nucleic acids into donor platelets. Internalization of specific nucleic acids by platelets will lead to the production of new pro-coagulant proteins, priming them for potent response to a bleeding event. Enhancing the natural coagulability of platelets will improve options for bleeding control after trauma, hopefully reducing the number of hemorrhage related deaths. Platelets have also been implicated in cancer and inflammatory diseases and enhancing coagulability using gene therapy will provide proof-of-concept that modified platelets can be used as a platform to deliver therapeutics in a multitude of disease contexts.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449642
Name
Strong Colton
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Delivery of Factor Xa into transfusable platelets to increase their natural coagulability
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Coagulation; Factor Xa; Gene Therapy; Hemostasis; Lipid Nanoparticles; Mrna; Platelets; Severe Hemorrhage; Thrombosis; Transfusion Medicine
Abstract
Platelets are blood cells that detect and adhere to sites of vascular damage, where they release pro-coagulant contents to initiate blood clotting. Failure to control bleeding after injury, such as during trauma, childbirth and surgery, accounts for more than half of all operating room deaths. Platelet transfusion is an essential treatment option to stop severe bleeding, but is not always effective, especially after significant blood loss. A strategy to improve platelet function during severe bleeds is to manipulate their internal composition by adding additional pro-coagulant proteins that enhance their natural ability to form a blood clot. This project aims to genetically engineer donor platelets to produce new coagulation factors so that after administration, they stop bleeding faster and create stronger clots than unmodified platelets. Generating new coagulation factors in platelets will be achieved by using lipid nanoparticle (LNP) drug delivery technology. Similar LNPs that are being used in leading COVID-19 vaccine candidates developed by Moderna and BioNtech will be used to deliver nucleic acids into donor platelets. Internalization of specific nucleic acids by platelets will lead to the production of new pro-coagulant proteins, priming them for potent response to a bleeding event. Enhancing the natural coagulability of platelets will improve options for bleeding control after trauma, hopefully reducing the number of hemorrhage related deaths. Platelets have also been implicated in cancer and inflammatory diseases and enhancing coagulability using gene therapy will provide proof-of-concept that modified platelets can be used as a platform to deliver therapeutics in a multitude of disease contexts.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Strong, Colton
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~